HighTide Therapeutics HK$194.1 million IPO
We advised HighTide Therapeutics on its IPO and HKEX listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
WuXi XDC Cayman HK$3.68 billion IPO
The shares are listed on the HKEX
Genetron $126 million going-private transaction
We are separately advising Genetron and the special committee of its board on the transaction
Gracell Biotechnologies PIPE of ordinary shares and warrants
The company’s ADSs are listed on Nasdaq
Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing
Cutia Therapeutics HK$412.9 million IPO
We advised Cutia on its IPO and HKEX listing
MedSci Healthcare Holdings HK$608 million IPO
We advised MedSci on its IPO and HKEX listing
TMS ¥2.9 billion global IPO
The shares are listed on the Tokyo Stock Exchange
Biocytogen HK$549 million IPO
We advised Biocytogen on its IPO and HKEX listing
Jiangsu Zhongnan Construction Group exchange offers
The exchange offers involve guaranteed senior notes due this year